Hanlon Investment Management Inc. Increases Stock Position in Merck & Co., Inc. (NYSE:MRK)

Hanlon Investment Management Inc. increased its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 8.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,459 shares of the company’s stock after buying an additional 271 shares during the period. Hanlon Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $456,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in MRK. Norges Bank purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $3,108,366,000. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 6.7% during the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after purchasing an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Merck & Co., Inc. by 14.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock valued at $3,966,029,000 after purchasing an additional 4,731,152 shares in the last quarter. Bank of Nova Scotia lifted its holdings in Merck & Co., Inc. by 352.2% during the fourth quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock valued at $342,814,000 after purchasing an additional 2,449,211 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its holdings in Merck & Co., Inc. by 29,914.1% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock valued at $262,818,000 after purchasing an additional 2,402,700 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MRK. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research report on Monday, March 11th. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Truist Financial increased their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.00.

View Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $126.45 on Monday. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $134.63. The stock has a market cap of $320.27 billion, a P/E ratio of 140.50, a PEG ratio of 2.44 and a beta of 0.38. The company has a 50-day moving average price of $129.14 and a 200 day moving average price of $125.13. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same period last year, the business earned $1.40 earnings per share. Merck & Co., Inc.’s revenue was up 8.9% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 8.62 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is presently 342.22%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.